VJVirtual | GPS and NPS: novel immunotherapeutics from SELLAS

Angelos M. Stergiou, MD, ScD, SELLAS Life Sciences Group, New York, NY, discusses the origins of SELLAS Life Sciences, a late-stage pharmaceutical company developing novel cancer immunotherapeutics across a variety of cancer indications, focusing of galinpepimut-S (GPS), an immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein, as well as nelipepimut-S, a HER2-directed cancer immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).